YAVNE, Israel, May 8, 2014 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announced today the signing of an agreement granting Genfa Medica, S.A. exclusive rights to market and distribute NexoBrid® in Russia for the treatment of severe burns. Approximately 35,000 patients with severe burns are hospitalized every year in Russia at approximately 80 burn centers.
Help employers find you! Check out all the jobs and post your resume.
